Chemical Information | |
Antiviral agent ID | DrugRepV_1431 | |
Antiviral agent name | Biperiden Hydrochloride | |
IUPAC Name | 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol;hydrochloride | |
SMILES (canonical) | C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O.Cl | |
Molecular Formula | C21H30ClNO | |
Molecular Weight (g/mol) | 347.927 | |
InChl | InChI=1S/C21H29NO.ClH/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17;/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2;1H | |
Common Name | Biperiden HCl | |
Synonyms | Akineton | Biperiden hydrochloride | Biperiden HCl | Akinophyl | 1235-82-1 | |
Structural Information | |
|
|
Clinical Information | |
Category | Nervous System
| |
Primary Indication (Clinical trial phases) | Approved
| |
Biological Information | |
Primary Indication (Disease Category) | Non Infectious Disease
| |
Primary Indication (Disease) | Parkinson disease
| |
Secondary Indication | Zika virus (ZIKV) NA MEX_I_7 | |
Secondary Indication (Approaches) | Experimental-HTS | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | Huh-7
| |
Secondary Indication (Mode of viral infection) | Adsorption
| |
Secondary Indication (Viral titer) | 0.4 MOI
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Time of drug delivery) | Pre infection (1 hour)
| |
Secondary Indication (Duration of drug delivery) | 24-26 hours
| |
Secondary Indication (Drug concentration) | 13.8 μM
| |
Secondary Indication (Cell based assay) | Fluorescence-based assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | Percentage Inhibition [ 41.17 % ] | |
Reference | Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, Galarza-Muñoz.A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection..Cell Host Microbe. 2016 Aug 10;20(2):259-70. doi: 10.1016/j.chom.2016.07.004. Epub 2016 Jul 28. PMID:27476412
| |
Comment | Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis.
| |